FY2026 Earnings Estimate for Nevro Issued By William Blair

Nevro Corp. (NYSE:NVRO) – William Blair issued their FY2026 earnings per share (EPS) estimates for Nevro in a research note issued to investors on Tuesday, November 12th. William Blair analyst B. Vazquez expects that the medical equipment provider will earn ($2.46) per share for the year. The consensus estimate for Nevro’s current full-year earnings is ($2.60) per share.

Other equities analysts also recently issued reports about the company. Royal Bank of Canada reiterated a “sector perform” rating and set a $7.00 target price on shares of Nevro in a research report on Tuesday. Wells Fargo & Company cut shares of Nevro from an “equal weight” rating to an “underweight” rating and reduced their price objective for the company from $13.00 to $5.50 in a research report on Wednesday, August 7th. JPMorgan Chase & Co. lowered shares of Nevro from a “neutral” rating to an “underweight” rating in a research report on Wednesday, August 7th. Piper Sandler reduced their price target on shares of Nevro from $7.00 to $6.00 and set an “underweight” rating on the stock in a report on Tuesday. Finally, Robert W. Baird increased their price objective on shares of Nevro from $5.00 to $6.00 and gave the company a “neutral” rating in a report on Tuesday. Three equities research analysts have rated the stock with a sell rating and twelve have assigned a hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $9.10.

Nevro Stock Performance

Shares of Nevro stock opened at $5.06 on Wednesday. Nevro has a 1-year low of $4.38 and a 1-year high of $22.64. The company’s fifty day simple moving average is $5.24 and its 200-day simple moving average is $7.48. The company has a current ratio of 4.77, a quick ratio of 3.53 and a debt-to-equity ratio of 0.66.

Nevro (NYSE:NVRO) last posted its quarterly earnings data on Monday, November 11th. The medical equipment provider reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.40. The company had revenue of $96.60 million for the quarter, compared to the consensus estimate of $93.09 million. Nevro had a negative net margin of 16.54% and a negative return on equity of 23.35%. The firm’s revenue was down 7.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.65) earnings per share.

Hedge Funds Weigh In On Nevro

Hedge funds have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. grew its position in Nevro by 490.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 728,463 shares of the medical equipment provider’s stock valued at $6,134,000 after acquiring an additional 605,134 shares during the last quarter. Millennium Management LLC boosted its position in Nevro by 21.4% in the 2nd quarter. Millennium Management LLC now owns 956,542 shares of the medical equipment provider’s stock valued at $8,054,000 after buying an additional 168,573 shares during the period. Point72 Asset Management L.P. grew its stake in Nevro by 3,446.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 152,500 shares of the medical equipment provider’s stock worth $1,284,000 after acquiring an additional 148,200 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of Nevro by 154.1% during the second quarter. Acadian Asset Management LLC now owns 241,186 shares of the medical equipment provider’s stock worth $2,029,000 after acquiring an additional 146,276 shares during the period. Finally, Algert Global LLC raised its stake in shares of Nevro by 57.3% during the second quarter. Algert Global LLC now owns 216,572 shares of the medical equipment provider’s stock valued at $1,824,000 after acquiring an additional 78,895 shares in the last quarter. 95.52% of the stock is currently owned by institutional investors.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.